Blue­bird’s new gene ther­a­py among three new EMA OKs ahead of FDA

Ahead of a usu­al­ly speedy FDA, the Eu­ro­pean Med­i­cines Agency on Fri­day rec­om­mend­ed mar­ket­ing au­tho­riza­tions for blue­bird bio’s new gene ther­a­py for chil­dren with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER